Medtronic affera™ pulsed field ablation technologies continue to demonstrate promising evidence for atrial fibrillation patients

One-year clinical trial data for the next-generation, investigational, sphere-360™ single-shot pfa catheter show impressive safety, performance, and efficiency results for paroxysmal afib dual-energy (rf/pf), focal sphere-9™ catheter demonstrates efficacy for linear ablation in persistent afib medtronic continues legacy of leadership in innovation, showcasing arrhythmia management portfolio at heart rhythm society annual meeting galway, ireland and san diego , april 26, 2025 /prnewswire/ -- medtronic plc (nyse: mdt), a global leader in healthcare technology, today announced positive clinical outcomes from two studies in atrial fibrillation (afib) patients treated with the affera™ family of technologies, including the next-generation sphere-360™ single-shot pulsed field ablation (pfa) catheter and the groundbreaking sphere-9™ combination mapping and dual-energy focal pfa catheter. data were presented in high impact science sessions at the heart rhythm society 2025 annual meeting in san diego; the sphere-360 study was simultaneously published in the heart rhythm journal.
MDT Ratings Summary
MDT Quant Ranking